神经药理学报 ›› 2024, Vol. 14 ›› Issue (1): 33-.DOI: 10.3969/j.issn.2095-1396.2024.01.006

• 研究论文 • 上一篇    下一篇

肺纤康颗粒联合汉防己甲素片治疗尘肺病的疗效及对肺功能和血清IL-8、IFN-γ 水平的影响

秦娜,武晓兰,周小番,龙照,廖梓君   

  1. 1. 衡阳市中医医院门急诊,衡阳,421001,中国 

    2. 衡阳市中医医院护理部,衡阳,421001,中国 

    3. 衡阳市中医医院职业病科,衡阳,421001,中国 

    4. 衡阳市中医医院神经内科,衡阳,421001,中国 

    5. 衡阳市中医医院老年病科,衡阳,421001,中国

  • 出版日期:2024-02-26 发布日期:2024-05-24
  • 作者简介:秦娜,主治医师,本科;研究方向:中医内科和职业病防治;E-mail: 15580302499@163.com
  • 基金资助:
    肺纤康颗粒治疗气虚血瘀型煤工尘肺的临床研究(No.hyzdxjh202103)

Efficacy of Feixiankang Granules Combined with Tetrandrine Tablets in Treatment of Pneumoconiosis and Its Effect on Lung Function and Serum IL-8 and IFN-γ Levels

QIN Na, WU Xiao-lan, ZHOU Xiao-fan, LONG Zhao, LIAO Zi-jun   

  1. 1. Outpatient and Emergency Department of Hengyang Hospital of Traditional Chinese Medicine, Hengyang, 421001, China 

    2. Nursing Department of Hengyang Hospital of Traditional Chinese Medicine, Hengyang, 421001, China 

    3. Department of Occupational Diseases, Hengyang Hospital of Traditional Chinese Medicine, Hengyang, 421001, China 

    4. Department of Neurology, Hengyang Hospital of Traditional Chinese Medicine, Hengyang, 421001, China 

    5. Department of Geriatrics, Hengyang Hospital of Traditional Chinese Medicine, Hengyang, 421001, China

  • Online:2024-02-26 Published:2024-05-24

摘要:

目的:探讨肺纤康颗粒联合汉防己甲素片治疗尘肺病的疗效及对肺功能和血清白介素-8(interleukin-8, IL-8)、γ-干扰素(interferon-γ, IFN-γ)水平的影响。方法:选取2021年6月~2023年5月衡阳市中医院职业 病科门诊或住院收治的72例尘肺病患者为研究对象。按照随机数字表法将患者分为对照组(n=36)和观察组 (n=36)。两组均给予常规对症治疗,对照组在此基础上给予汉防己甲素片治疗,观察组在对照组基础上联合使 用肺纤康颗粒治疗。治疗3个月后,比较两组临床疗效、中医症候积分、肺功能[最大通气量(maximum ventilation volume, MVV)及第1秒用力呼气容积(forced expiratory volume in one second, FEV1)]、血清IL-8、IFN-γ水平 及治疗期间不良反应。结果:观察组总有效率高于对照组(P<0.05)。治疗后,两组中医症候主要症状积分、次要 症状积分及总分均下降(P<0.05),且观察组更低(P<0.05)。治疗后,两组MVV及FEV1均上升(P<0.05),且观察 组更高(P<0.05);两组IL-8均下降(P<0.05),且观察组更低(P<0.05);两组IFN-γ均上升(P<0.05),且观察组更高 (P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论:尘肺病患者给予肺纤康颗粒联合汉防己甲素 片治疗可显著提高患者疗效,改善其肺功能,降低血清IL-8水平,提高IFN-γ水平。

关键词: 尘肺病, 肺纤康颗粒, 汉防己甲素片, 肺功能, 炎症因子

Abstract:

Objective: To investigate the efficacy of Feixiankang Granules combined with Tetrandrine Tablets in the treatment of pneumoconiosis and its effect on lung function and serum IL-8 and IFN-γ levels. Methods: From June 2021 to May 2023,72 patients with pneumoconiosis admitted to the outpatient or inpatient department of the occupational disease department of Hengyang Hospital of Traditional Chinese Medicine were selected as the research objects. According to the random number table method, the patients were randomly divided into control group(n=36) and observation group (n=36). Both groups were given conventional symptomatic treatment. The control group was treated with tetrandrine tablets on this basis, and the observation group was treated with Feixiankang granules on the basis of the control group. After 3 months of treatment, the clinical efficacy, TCM symptom scores, lung function [maximum ventilation volume (MVV) and forced expiratory volume in one second (FEV1)], serum IL-8, IFN-γ levels and adverse reactions during treatment were compared between the two groups. Results: The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the scores of main symptoms, secondary symptoms and total scores of TCM symptoms in the two groups decreased(P<0.05), and those in the observation group were lower(P<0.05). After treatment, MVV and FEV1 in both groups increased (P<0.05), and those in the observation group were higher(P<0.05). IL-8 decreased in both groups(P<0.05), and the observation group was lower(P<0.05). IFN-γ in both groups increased(P<0.05), and the observation group was higher(P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05). Conclusion: Feixiankang granule combined with tetrandrine tablets can significantly improve the curative effect, improve lung function, reduce serum IL-8 level and increase IFN-γ level in patients with pneumoconiosis.

Key words: pneumoconiosis, feixiankang granules, tetrandrine tablets, lung function, inflammatory factors